Increased Doses of Gleevec® for Gleevec-Resistant Gastrointestinal Stromal Tumors (GIST) Effective According to a recent article published in the European Journal of Cancer, increasing doses of Gleevec®... Continue Reading

Protein Mutations May Predict Outcomes for GIST Patients Treated with Gleevec® During a recent presentation at the 2005 annual meeting of the American Society of Clinical Oncology, researchers reported... Continue Reading

SU11248 Effective in Gastrointestinal Stromal Tumors (GIST) According to results from a recent clinical trial, the multi-targeted agent SI11248 is effective in the treatment of gastrointestinal stromal... Continue Reading

Increased Doses of Gleevec® More Effective in Gastrointestinal Stromal Tumors According to a recent article published in the Lancet, increasing the dose of Gleevec® (imatinib mesylate) reduces the risk... Continue Reading

Imatinib Improves Survival in GISTs According to a recent article published in The Lancet, imatinib (formerly STI-571) is well tolerated and significantly improves survival in patients with advanced... Continue Reading